MedTrace Logo

Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy

NCT03322345 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2025-03-13

No results posted yet for this study

Summary

Patients that have undergone a Fontan procedure (surgical correction for single ventricle congenital heart disease) may develop a complication known as protein-losing enteropathy (PLE). Some studies suggest PLE is primarily caused by impaired lymph flow. Use of continuous dopamine infusion can improve PLE. Evidence suggests the effect of dopamine may be through its effect on lymphatic function. This observational study looks at markers of lymph flow and PLE symptoms after treatment using dopamine and other standard therapies during disease exacerbations.

Conditions

  • Dopamine
  • Protein-Losing Enteropathies
  • Lymphatic System
  • Lymph
  • Catecholamine
  • Single-ventricle
  • Congenital Heart Disease

Sponsors & Collaborators

Principal Investigators

  • Kurt Schumacher, MD, MS · University of Michigan Division of Pediatric Cardiology

  • Joshua Meisner, MD, PhD · University of Michigan Division of Pediatric Cardiology

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2027-04-01
Completion
2027-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322345 on ClinicalTrials.gov